WindMIL Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 2 Study of Marrow Infiltrating Lymphocytes (MILs™) in Non-Small Cell Lung Cancer - GlobeNewswire

WindMIL Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 2 Study of Marrow Infiltrating Lymphocytes (MILs™) in Non-Small Cell Lung Cancer  GlobeNewswire

BALTIMORE and PHILADELPHIA, June 25, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating ...